Media stories about Acorda Therapeutics (NASDAQ:ACOR) have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acorda Therapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.7385342657911 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 – ACOR (finance.yahoo.com)
- Acorda Therapeutics to Present at the 36th Annual J.P. Morgan … – Business Wire (press release) (businesswire.com)
- Acorda Therapeutics, Inc. (ACOR) Given Average Recommendation of “Hold” by Analysts (americanbankingnews.com)
- Kessler Topaz Meltzer & Check, LLP Announces Shareholder Lawsuit Filed against Acorda Therapeutics, Inc. (finance.yahoo.com)
- Acorda Therapeutics Inc (NASDAQ:ACOR): Earnings Expected To Remain Subdued (finance.yahoo.com)
Several research firms have issued reports on ACOR. HC Wainwright set a $34.00 price target on Acorda Therapeutics and gave the company a “buy” rating in a report on Thursday, December 14th. Piper Jaffray Companies reaffirmed a “neutral” rating and issued a $22.00 price target on shares of Acorda Therapeutics in a report on Tuesday, November 28th. TheStreet cut Acorda Therapeutics from a “c-” rating to a “d+” rating in a report on Friday, November 17th. Cowen reaffirmed a “buy” rating and issued a $30.00 price target on shares of Acorda Therapeutics in a report on Friday, November 17th. Finally, Janney Montgomery Scott set a $17.00 price target on Acorda Therapeutics and gave the company a “hold” rating in a report on Thursday, November 16th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $21.47.
Acorda Therapeutics (NASDAQ:ACOR) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.69 by ($0.26). Acorda Therapeutics had a negative net margin of 10.25% and a negative return on equity of 8.18%. The firm had revenue of $141.07 million for the quarter, compared to analyst estimates of $150.64 million. During the same period last year, the firm earned ($0.04) earnings per share. Acorda Therapeutics’s revenue for the quarter was up 4.0% compared to the same quarter last year. analysts expect that Acorda Therapeutics will post -0.15 EPS for the current year.
In other news, insider Burkhard Blank sold 11,050 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $20.53, for a total transaction of $226,856.50. Following the transaction, the insider now directly owns 33,150 shares in the company, valued at approximately $680,569.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 7.90% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Acorda Therapeutics (ACOR) Stock Price” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.com-unik.info/2017/12/27/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-acorda-therapeutics-acor-stock-price.html.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.